Medical Device Dec 3, 2025
Potential for backflow of medication from secondary (piggyback) IV containers into primary IV containers and the inability to prime (occlusion).
Class II FDA: Ongoing B Braun Medical Inc.
Medical Device Dec 3, 2025
Potential for backflow of medication from secondary (piggyback) IV containers into primary IV containers and the inability to prime (occlusion).
Class II FDA: Ongoing B Braun Medical Inc.
Medical Device Dec 3, 2025
Potential for backflow of medication from secondary (piggyback) IV containers into primary IV containers and the inability to prime (occlusion).
Class II FDA: Ongoing B Braun Medical Inc.
Medical Device Dec 3, 2025
Potential for backflow of medication from secondary (piggyback) IV containers into primary IV containers and the inability to prime (occlusion).
Class II FDA: Ongoing B Braun Medical Inc.
Medical Device Dec 3, 2025
Potential for backflow of medication from secondary (piggyback) IV containers into primary IV containers and the inability to prime (occlusion).
Class II FDA: Ongoing B Braun Medical Inc.
Medical Device Dec 3, 2025
Potential for backflow of medication from secondary (piggyback) IV containers into primary IV containers and the inability to prime (occlusion).
Class II FDA: Ongoing B Braun Medical Inc.
Medical Device Dec 3, 2025
Tape used to secure components within packaging contains latex, despite products being labeled as latex-free. Latex could potentially cause an allergic reaction.
Class II FDA: Ongoing Stryker Corporation
Medical Device Dec 3, 2025
Potential for backflow of medication from secondary (piggyback) IV containers into primary IV containers and the inability to prime (occlusion).
Class II FDA: Ongoing B Braun Medical Inc.
Medical Device Dec 3, 2025
Potential for anesthesia leakage.
Class II FDA: Ongoing Mindray DS USA, Inc. dba Mindray North America
Medical Device Dec 3, 2025
Tape used to secure components within packaging contains latex, despite products being labeled as latex-free. Latex could potentially cause an allergic reaction.
Class II FDA: Ongoing Stryker Corporation
Medical Device Dec 3, 2025
Potential for backflow of medication from secondary (piggyback) IV containers into primary IV containers and the inability to prime (occlusion).
Class II FDA: Ongoing B Braun Medical Inc.
Medical Device Dec 3, 2025
Potential for backflow of medication from secondary (piggyback) IV containers into primary IV containers and the inability to prime (occlusion).
Class II FDA: Ongoing B Braun Medical Inc.
Medical Device Dec 3, 2025
Potential for backflow of medication from secondary (piggyback) IV containers into primary IV containers and the inability to prime (occlusion).
Class II FDA: Ongoing B Braun Medical Inc.
Medical Device Dec 3, 2025
Potential for backflow of medication from secondary (piggyback) IV containers into primary IV containers and the inability to prime (occlusion).
Class II FDA: Ongoing B Braun Medical Inc.
Medical Device Dec 3, 2025
Potential for backflow of medication from secondary (piggyback) IV containers into primary IV containers and the inability to prime (occlusion).
Class II FDA: Ongoing B Braun Medical Inc.
Medical Device Dec 3, 2025
Potential for backflow of medication from secondary (piggyback) IV containers into primary IV containers and the inability to prime (occlusion).
Class II FDA: Ongoing B Braun Medical Inc.
Medical Device Dec 3, 2025
Potential for backflow of medication from secondary (piggyback) IV containers into primary IV containers and the inability to prime (occlusion).
Class II FDA: Ongoing B Braun Medical Inc.
Medical Device Dec 3, 2025
Potential for backflow of medication from secondary (piggyback) IV containers into primary IV containers and the inability to prime (occlusion).
Class II FDA: Ongoing B Braun Medical Inc.
Medical Device Dec 3, 2025
Potential for backflow of medication from secondary (piggyback) IV containers into primary IV containers and the inability to prime (occlusion).
Class II FDA: Ongoing B Braun Medical Inc.
Medical Device Dec 3, 2025
Potential for backflow of medication from secondary (piggyback) IV containers into primary IV containers and the inability to prime (occlusion).
Class II FDA: Ongoing B Braun Medical Inc.
Medical Device Dec 3, 2025
Potential for backflow of medication from secondary (piggyback) IV containers into primary IV containers and the inability to prime (occlusion).
Class II FDA: Ongoing B Braun Medical Inc.
Medical Device Dec 3, 2025
Potential for backflow of medication from secondary (piggyback) IV containers into primary IV containers and the inability to prime (occlusion).
Class II FDA: Ongoing B Braun Medical Inc.
Medical Device Dec 3, 2025
Potential for backflow of medication from secondary (piggyback) IV containers into primary IV containers and the inability to prime (occlusion).
Class II FDA: Ongoing B Braun Medical Inc.
Medical Device Dec 3, 2025
Potential for backflow of medication from secondary (piggyback) IV containers into primary IV containers and the inability to prime (occlusion).
Class II FDA: Ongoing B Braun Medical Inc.